Adding details of deal and context

June 30 (Reuters) - Hong Kong-listed drug design tech firm Metis TechBio 7666.HK said on Tuesday it has granted U.S.-based biotechnology firm Boulevard Bio exclusive global rights to develop, manufacture and commercialise its experimental autoimmune drug MTS-128 in a deal that could be worth up to $1.6 billion.

The deal marks an advancement for U.S.-China tech collaboration as Beijing ramps up scrutiny of cross-border deals involving sensitive technologies.

• Under the terms, Boulevard will secure worldwide rights to develop, manufacture and commercialise MTS-128

• Metis TechBio is eligible to receive $20 million as an upfront payment and up to $1.6 billion in additional payments tied to development, regulatory and commercial-related milestones.

• Metis TechBio said in a filing to the Hong Kong stock exchange that MTS-128's successful development demonstrated the firm's capability to "deeply integrate artificial intelligence with protein drug design".

• MTS-128 is for the autoimmune indication, according to Metis TechBio's website.

• Metis TechBio did not immediately respond to a request for comment on which disease area MTS-128 targeted.

• Beijing has tightened scrutiny of U.S. investment in domestic firms developing frontier technologies.

• This year, China ordered U.S. tech giant Meta META.O to unwind its $2 billion-plus acquisition of AI startup Manus.